Abstract | UNLABELLED: METHODS: RESULTS: Both (125)I- and (111)In-labeled MG1 preferentially accumulated in intraperitoneal CC-531 tumors. The uptake of (111)In-MG1 in tumor was higher than that of (125)I-MG1 (4.1 +/- 2.3 %ID/g vs. 1.1 +/- 0.5 %ID/g [%ID/g is percentage of injected dose per gram], 72 h after injection; P = 0.053). Radiommunotherapy with 74 MBq (177)Lu-MG1 almost completely eradicated tumor growth, whereas unlabeled MG1 had no effect. In the surgery study, both cytoreductive surgery and radiommunotherapy were well tolerated. The median survival of the control rats that underwent exploratory laparotomy only was 41 d. The median survival of the rats that were treated with cytoreductive surgery only, exploratory laparotomy + radiommunotherapy, or cytoreductive surgery + radiommunotherapy was 51 d (P = 0.05 compared with control rats), 61.5 d (P = 0.03), and 88 d (P = 0.0001), respectively, which suggests an additive effect of both treatment modalities. There was a highly significant trend toward improved survival of cytoreductive surgery + radiommunotherapy compared with both monotherapies (P = 0.0004). CONCLUSION: This study provides proof of principle that radiommunotherapy can be an effective treatment modality when applied as an adjuvant treatment after resection of tumors with a high risk of recurrence, such as after cytoreductive surgery of peritoneal carcinomatosis.
|
Authors | Manuel J Koppe, Thijs Hendriks, Otto C Boerman, Wim J G Oyen, Robert P Bleichrodt |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 47
Issue 11
Pg. 1867-74
(Nov 2006)
ISSN: 0161-5505 [Print] United States |
PMID | 17079821
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Iodine Radioisotopes
|
Topics |
- Adjuvants, Immunologic
(therapeutic use)
- Animals
- Body Weight
- Cell Line, Tumor
- Clinical Trials as Topic
- Colonic Neoplasms
(surgery, therapy)
- Disease Models, Animal
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Male
- Neoplasms
(radiotherapy, therapy)
- Peritoneal Neoplasms
(surgery, therapy)
- Radioimmunotherapy
(methods, trends)
- Radiotherapy Dosage
- Rats
|